Health
Deactivating gene could boost immunotherapy for head and neck cancer – Drug Target Review
Inhibiting the KDM4A enzyme slowed the growth of head and neck cancer in mouse models, also demonstrating promise to aid immunotherapy.
Posted: 24 March 2021 | Victoria Rees (Drug Target Review) | No comments yet
Inhibiting the KDM4A enzyme slowed the growth of head and neck cancer in mouse models, also demonstrating promise to aid immunotherapy.
By targeting an enzyme that plays a key role in head and neck cancer cells, researchers were able to significantly slow the growth and spread of tumours in mice and enhance the effectiveness of an immunotherapy to which these types of cancers often become resistant. The study was conducted…
-
General15 hours agoChina and Philippines trade blame over latest South China Sea clash
-
Noosa News20 hours agoBrisbane rising on global rankings, but still behind southern capitals
-
Noosa News20 hours agoWest End icon closes doors
-
General22 hours agoCalls for government to ‘get on with’ CSIRO Ginninderra Experiment Station land sale after three-year delay